Puma Biotechnology (PBYI) EBITDA Margin (2017 - 2026)
Puma Biotechnology (PBYI) reported EBITDA Margin of 8.54% for Q1 2026, down 1720.0% on a YoY basis from 0.53% in Q1 2025, and down 137.68% quarter-over-quarter from 22.67% in Q4 2025.
Puma Biotechnology (PBYI) EBITDA Margin (2017 - 2026) Analysis & Trends
Puma Biotechnology has reported EBITDA Margin for 10 years, with the latest figure at 8.54% in Q1 2026.
- For the quarter ending Q1 2026, EBITDA Margin fell 1720.0% year-over-year to 8.54%; the trailing twelve-month figure through Mar 2026 stood at 12.98% (down 303.0% YoY), and the FY2025 full-year result was 16.33%, up 290.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 8.54%, down from 22.67% in the prior quarter.
- The five-year high for EBITDA Margin was 27.41% in Q3 2024, with the low at 8.54% in Q1 2026.
- Historically, EBITDA Margin has averaged 10.61% across 5 years, with a median of 11.43% in 2022.
- The largest YoY upside for EBITDA Margin was 5142 bps in 2022 against a maximum downside of 2216 bps in 2022.
- Puma Biotechnology's EBITDA Margin stood at 11.43% in 2022, then surged by 79 bps to 20.5% in 2023, then grew by 10 bps to 22.62% in 2024, then gained by 0 bps to 22.67% in 2025, then slumped by 138 bps to 8.54% in 2026.
- The last three EBITDA Margin figures came in at 8.54% (Q1 2026), 22.67% (Q4 2025), and 17.57% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Puma Biotechnology | 384.39 Mn | 282.84 Mn | 34.39 Mn | -8.54% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.54% |
| Dec 31, 2025 | 22.67% |
| Sep 30, 2025 | 17.57% |
| Jun 30, 2025 | 12.66% |
| Mar 31, 2025 | 8.66% |
| Dec 31, 2024 | 22.62% |
| Sep 30, 2024 | 27.41% |
| Jun 30, 2024 | -4.63% |
| Mar 31, 2024 | -5.25% |
| Dec 31, 2023 | 20.50% |
| Sep 30, 2023 | 15.30% |
| Jun 30, 2023 | 8.96% |
| Mar 31, 2023 | 8.27% |
| Dec 31, 2022 | 11.43% |
| Sep 30, 2022 | 4.19% |
| Jun 30, 2022 | 20.26% |
| Mar 31, 2022 | -1.63% |
| Dec 31, 2021 | -0.91% |
| Sep 30, 2021 | -19.36% |
| Jun 30, 2021 | -31.16% |